Literature DB >> 10886540

Hepatitis C is more severe in drug users with human immunodeficiency virus infection.

R Romeo1, M G Rumi, M F Donato, M A Cargnel, P Viganò, M Mondelli, B Cesana, M Colombo.   

Abstract

Drug users with chronic hepatitis C virus (HCV) infection are frequently co-infected with human immunodeficiency virus-1 (HIV-1), but it is still not clear whether HIV-1 worsens the natural history of hepatitis C. To investigate this, we conducted a multicentre observational study in 163 drug addicts with histologically documented hepatitis C, 92 of whom were also infected with HIV-1: 25 (27%) were CDC stage II, 53 (58%) were CDC stage III and 14 (15%) were CDC stage IV. Eighty-eight (54%) patients had chronic hepatitis (CH) with minimal activity, 28 (17%) had CH with moderate activity, 40 (25%) had CH with severe activity and seven (4%) had active cirrhosis. Twenty-one HIV-negative patients and 15 HIV-positive patients admitted to alcohol abuse (29% vs 16%, P=0.0665). Liver disease was more severe in HIV-positive patients than in HIV-negative ones (P=0.0198): 34 HIV-positive patients and 13 HIV negatives had severe CH and cirrhosis. These two severe liver diseases were seen more often in HIV-positive patients with a history of alcohol abuse than in HIV-negative patients (10 out of 16 vs seven out of 21). Age, alcohol abuse and distribution of the histological categories of liver disease were statistically different in HIV-infected and HIV-uninfected patients. Multivariate analysis showed that age, alcohol abuse and serum antibodies to HIV were independently associated with severe CH or cirrhosis. Thus, HIV may enhance the risk of severe liver disease in drug users with hepatitis C, independently of the degree of immune dysfunction. Alcohol abuse may contribute independently, aggravating the cause of HCV-dependent liver disease.

Entities:  

Mesh:

Year:  2000        PMID: 10886540     DOI: 10.1046/j.1365-2893.2000.00230.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

2.  The urgency of providing comprehensive and integrated treatment for substance abusers with HIV.

Authors:  Nora D Volkow; Julio Montaner
Journal:  Health Aff (Millwood)       Date:  2011-08       Impact factor: 6.301

3.  Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study.

Authors:  Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-27       Impact factor: 2.890

4.  Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study.

Authors:  D Sène; S Pol; L Piroth; C Goujard; P Dellamonica; J Moussali; D Rey; V Loustaud-Ratti; L Alric; M Chousterman; F Borsa-Lebas; O Boucher; D Séréni; P Cacoub
Journal:  Epidemiol Infect       Date:  2006-07-25       Impact factor: 2.451

5.  Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugs.

Authors:  Milena Furione; Renato Maserati; Marta Gatti; Fausto Baldanti; Agostino Cividini; Raffaele Bruno; Giuseppe Gerna; Mario U Mondelli
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 6.  Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Authors:  Vincent Lo Re; Jay R Kostman; Valerianna K Amorosa
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

7.  HBV and HCV seroprevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest Ethiopia.

Authors:  Yitayih Wondimeneh; Meseret Alem; Fanaye Asfaw; Yeshambel Belyhun
Journal:  Virol J       Date:  2013-05-30       Impact factor: 4.099

8.  Hepatitis B and C co-infection in HIV/AIDS population in the state of Michigan.

Authors:  Z A Butt; M J Wilkins; E Hamilton; D Todem; J C Gardiner; M Saeed
Journal:  Epidemiol Infect       Date:  2013-03-12       Impact factor: 4.434

Review 9.  Therapeutic issues in HIV/HCV-coinfected patients.

Authors:  M S Sulkowski; Y Benhamou
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.